ENGN$1.54+5.86%
enGene Therapeutics Inc.
Sector: Biological Products, (No Diagnostic Substances)Industry: BiotechnologyCountry: CAExchange: Nasdaq
Mkt Cap:$102.87M
Float & O/S:
Inst Own:
DilutionScan read 32 of enGene Therapeutics Inc.'s SEC filings and found 5 warrant series, 2 convertibles, 2 ATM programs, 3 shelf registrations, 1 S-1 registration and 1 completed offering on file for ENGN. The latest dilution event on file is ATM sales on Jul 31, 2026. Analysis updated Oct 6, 2026.
Signal8 Summary
19d old
ENGN
Pre-revenue biotech funded through BLA filing
- Business
- MixedNo revenue, $117M net loss, but $266.3M cash, 28-month runway
- Stock risk
- High$104.5M micro-cap, shares +14.5% YoY, 113% overhang supply
Snapshot
enGene is a clinical-stage biotech with no revenue, posting a $117.3M net loss in FY 2025 and burning roughly $100.7M in free cash flow. It holds $266.3M in cash against modest $33.3M debt, and Signal8 models about 28 months of runway.
What's Happening Right Now
- : enGene will host an October 15, 2026 webinar detailing preclinical data behind pairing a surfactant bladder rinse with detalimogene in its NMIBC program.
- : The Q3 10-Q showed a $32.5M quarterly net loss and $464.5M accumulated deficit; the company cut its workforce ~50% in June 2026 to preserve cash and still plans a BLA submission in Q4 2026.
- : enGene reported Q3 FY2026 results, with focus shifting to maturing LEGEND pivotal-cohort data and an upcoming FDA engagement on a BLA filing for detalimogene.
- : An updated corporate presentation on July 24, 2026 showed the pivotal cohort's 54% complete response rate and 43% six-month response rate, with a planned BLA submission in H2 2026.
- : Chairman Richard Glickman resigned effective July 15, 2026 after 14+ years; director Michael Heffernan was appointed as the new Chairman.
- : Registered $400.00M of securities for sale on Form S-3.
- : Issued warrants over 41K shares.
- : Raised $149.50M in gross proceeds through a public offering, with warrants over 2.74M shares.
